Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
... interferon. The study in treatment naive genotype
1 infected subjects was of standard design, ... open-label study in 278 treatment-naive, genotype
1 patients evaluating taribavirin at weight-based ... disclosed as Study 204), 278 treatment naive, genotype
1 patients were randomized with the following ...
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
... at 800 mg bid, 2.9 log10 (range of 2.2 to 3.4). genotype
1a patients demonstrated median reductions of 1.4 ... 400 and 800 mg bid, respectively. In 10 of the 12 genotype
1a patients who received ANA598, viral load was ... at the end of the three days of treatment. genotype
1b patients demonstrated median reductions of 2.6 ...
INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients
... 14 days in treatment-experienced patients with genotype
1 HCV infection who have been previously treated ... F consists of null responder HCV patients with genotype
1 infection who have been treated with pegylated ... patients chronically infected with HCV genotype
1. The original study protocol consisted of four ...
Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
... of hepatitis C virus (HCV) replication in HCV genotype
1-derived replicon cell lines, and in vitro ... with chronic hepatitis C infected with HCV genotype
4. Phase II clinical trials are ongoing in the United States in patients with HCV genotype
About Romark Laboratories
Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C
... in treatment-naive patients infected with HCV genotype
4, 82% (n=17) and 100% (n=16) of patients ... activity in a small number of patients with HCV genotype
4. We look forward to reporting interim data from ... tablet in patients with chronic hepatitis C genotype
1 later this year."
In the Phase I study, ...
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
... day add-on study with R7128 in non-responder, HCV genotype
2 and genotype
3 patients in first half of 2009;
-- Report ... add-on study with R7128 in treatment naive, HCV genotype
1 patients in first half of 2009;
-- Report ...
Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
... enroll about 400 treatment naive, genotype-1 or genotype
4 HCV-infected patients. The trial will evaluate ... patients chronically infected with HCV genotype
1, R7128 demonstrated significant short-term ... in 81 treatment-naive patients infected with HCV genotype
Results with ...
Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
... laboratory test which determines haptoglobin genotype
useful in selecting and guiding patient ... clinics in Israel underwent
testing and were randomized to receive either ... it was determined that
those who had the Hp2-2 genotype
and who also received vitamin E had ...
Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
new clinical test to determine haptoglobin (Hp) genotype
intellectual property licensed from Synvista is now available. Knowledge of
may help physicians to assess cardiovascular risk ... individuals with
diabetes mellitus and the Hp2-2 genotype
(Hp2-2 Diabetes) demonstrate a
Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008
... nitazoxanide and peginterferon in genotype
4 patients and provide a
first look at sustained ... In this Phase II study, 44 patients (40 with HCV genotype
4; 3 with HCV
genotype 1; and 1 with HCV genotype
2) received 4 weeks of nitazoxanide 500
mg twice ...
GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology
... is particularly positioned for use in HCV genotype
1 which has
become the predominant genotype
worldwide and which is the most difficult
to treat, as well as in patients infected with HCV genotype
3 because of
the following properties:
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
... of treatment-naive patients
infected with HCV genotype
1. Multiple ascending doses were examined up to
a ... 14 days to strictly defined non-responders: HCV genotype
patients who had failed to achieve a 2.0 log10 ... Treatment of Chronic Hepatitis C Virus (HCV) genotype
Patients with the NS3/4A Protease Inhibitor ...
Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
... - 90% of genotype
2 or 3 patients achieve undetectable HCV RNA ... chronically infected with hepatitis C virus (HCV) genotype
2 or 3
who had not achieved a Sustained Viral ... demonstrated significant
antiviral activity in genotype
2 or 3 patients who had failed ...
Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
... it has been established that the Haptoglobin genotype
independent risk factor for cardiovascular ... in people with both diabetes and
the Hp 2-2 genotype
(approximately 40 percent of all diabetes ... diagnostic test to
determine haptoglobin genotype
in order to identify the subset of diabetics
Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
... prior non-responders and R7128 1000mg BID in HCV genotype
1 treatment-naive patients ... 1000mg BID in treatment-naive patients with
1. This cohort is intended to provide clinical ... patients chronically infected
with HCV genotype
1 will be presented at the 43rd Annual Meeting of ...
Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
... in 60 patients with
chronic hepatitis C genotype
1 who have failed to respond to standard
therapy ... and
naive patients with chronic hepatitis C genotype
4, is a phase II
randomized controlled trial ... States in 60 patients with chronic hepatitis
1 who have previously failed to respond to ...
Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
... within the next several weeks.
In the Phase II study, naive genotype
1 patients will receive ANA598 or placebo in combination with Pegasys(R) ... antiviral activity and good tolerability. In a monotherapy study in naive genotype
1 patients, treatment with ANA598 for three days led to median declines in ...
ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection
... a Phase Ib study of ANA598 in HCV patients. In the Phase Ib study, naive genotype
1a and 1b patients are to receive ANA598 over three days at doses of 200 ... Inadequate response rates, in particular for patients infected with genotype
1 HCV, along with significant side effects of approved therapy, support ...
Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco
... trial to evaluate nitazoxanide for the treatment of
chronic hepatitis C genotype
1 (STEALTH C-3). The STEALTH C-3 (Studies to
Evaluate Alinia for Treatment ... Roche) in treatment naive patients with chronic hepatitis C
infected with genotype
1. The primary objective of this trial is to
evaluate sustained virologic ...
Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
... and unfavorable (13%).
In the study, patients with the very favorable genotype
significant improvements in clinical endpoints compared to ... While the most robust clinical effects
occurred in the very favorable genotype
group, patients with the favorable
genotype also benefitted from treatment ...
Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments
... - Albuferon(R) Phase 3 trial in genotype
1 hepatitis C completes treatment phase -
- ... ACHIEVE 2/3 in April 2008. ACHIEVE 1 is
being conducted in patients with genotype
1 chronic hepatitis C; ACHIEVE
2/3 is being conducted in patients with ...
MIGENIX Corporate Update and Requisition of Special Meeting
... drugs alone for up to 12 weeks of therapy in
treatment-naive HCV infected genotype
1 patients is in the final stages of
completion. Results from the study ... in the next several weeks.
A previous Phase II study in non-responder genotype
1 patients provided
proof of concept in that HCV patient population (see ...
MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
... a satisfactory outcome for
approximately 50% of patients infected with HCV genotype
1 (the most
in North America).
MIGENIX is committed to advancing ...
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
... study of ANA598 in combination with pegylated interferon-alpha and ribavirin for the treatment of chronic hepatitis C. In the Phase II study, naive genotype
1 patients will receive ANA598 or placebo in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin, USP) (a current standard ...
Atherotech Taps Canyons Medical Center Director, Lipidologist as Chief Medical Officer
The company also provides more than a dozen cardiovascular and metabolic testing panels, including
C-Reactive Protein (hsCRP), ApoE genotype
and NT-proBNP for assessment of patients at intermediate to high risk of cardiometabolic diseases. Atherotech continues to add advanced and follow-up ...
Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease
... may produce lasting effects in those patients with this combination of genotypic markers.
The combination of the E4(-); IDE_7(C/C)(-) genotype
is prevalent in approximately 40% of the AD population, so the number of potential responder patients is substantial.
"This pharmacogenomic ...
Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
... intends to initiate the trial during the third quarter of 2009.
The current protocol design calls for 12 weeks of dosing ANA598 in naive genotype
1 patients in combination with SOC, compared to a control arm that will receive a placebo and SOC. After 12 weeks, patients are expected to continue ...
Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
... that its development partner, Roche, had initiated dosing of patients in the phase 2b trial of R7128 in combination with the standard of care in genotype
1 and 4 HCV infected patients. The start of the trial triggered a $10.0 million milestone payment to Pharmasset that is expected to be received in ...
Avian Adenovirus Genotyping Diagnostic Service
... use of boot strapping analysis on extended genetic sequences allows the investigator to arrive at statistically significant conclusions regarding the genotype
of a strain and its association with another strain. Thus the technology is ideally suited to determine if an adenovirus isolated from one flock is ...
Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments
... endpoint of non-inferiority to Pegasys (peginterferon alfa-2a) in ACHIEVE 1, a Phase 3 clinical trial of Albuferon in treatment-naive patients with genotype
1 chronic hepatitis C. As previously reported, Albuferon also met its primary endpoint in ACHIEVE 2/3, which was conducted in treatment-naive ...
InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
... and Ribavirin in Patients with Chronic Hepatitis C Virus (HCV).
Incidence of Virologic Escape Observed During ITMN-191 Monotherapy is genotype
Dependent, Associated with a Specific NS3 Substitution, and Suppressed Upon Combination with Peginterferon alfa-2a/Ribavirin .
Human Genome Sciences to Sponsor Conference Call
... that it will sponsor a conference call to discuss the results of its ACHIEVE 1 Phase 3 trial of Albuferon(R) (albinterferon alfa-2b) in patients with genotype
1 chronic hepatitis C.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )
The conference call will be hosted by senior ...
Pigs to Be Genotyped to Improve Selection and Breeding for Pancreatic Islet Cell Research
... that are naturally superior donors of pancreatic islet tissue for diabetes cure.
GeneSeek will take samples from Spring Point Project's pigs to genotype
for over 60,000 DNA markers using the new Infinium HD Porcine SNP60 Bead Chip from Illumina, Inc. (San Diego, CA). This will provide Spring Point ...
Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
... further analysis. We look forward to results from the ACHIEVE 1 trial, which is evaluating albinterferon alfa-2b in the treatment of patients with genotype
1 hepatitis C."
In the randomized, multi-center, active-controlled non-inferiority Phase 3 trial, 933 treatment-naive patients with ...
InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
... antiviral compounds when used in monotherapy for 14 days in treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype
1. - Excellent safety and tolerability for ITMN-191 in all dosage regimens. - The in-vitro combination of ITMN-191 with the active ...
Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
... current standard of care is a combination of pegylated interferon
and ribavirin. Inadequate response rates, in particular for patients
infected with genotype
1 HCV, along with significant side effects of
approved therapy support the medical need for improved treatment options.
It is estimated that fewer ...
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
... for the treatment
of hepatitis C virus (HCV) infection, and expects to initiate patient
dosing shortly. ANA598 will be administered to naive genotype
1a and 1b
patients at 200 mg bid (twice-a-day), 400 mg bid or 800 mg bid over a
period of three days. Anadys expects to have viral load data from ...
FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
... mortality, heart failure hospitalization, and
cardiovascular hospitalization. While the most robust clinical effects
occurred in the very favorable genotype
group, patients with the favorable
genotype also benefited from treatment with bucindolol. Bucindolol also
demonstrated clinically significant ...
As personalized, genomic medicine takes off, four developing countries show the way for others
... and linguistic subpopulations.
Meanwhile, an Indian life-sciences company, Avesthagen Ltd, has announced a five-year, $32 million project to genotype
the country's entire Parsi population -- about 69,000 people. The Parsis, thought to be genetically homogenous, are feared to be at risk owing to ...
Synvista Therapeutics Posts Letter to Stockholders on Web Site
... research, development and marketing. DIAGNOSTICS
We believe that we have a clear development pathway for our immunoassay
test to determine the 2-2 genotype
of Hp and have validated the accuracy of
a commercial kit, as presented at the 2008 Cardiovascular Biomarkers and
Surrogate Endpoints Symposium in ...